Are you Dr. D'Andrea?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 57 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2910 Toll Gate Dr
East Norriton, PA 19403Phone+1 610-631-2652
Summary
- Dr. Denise D'Andrea, MD is a nephrologist in East Norriton, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania, Alabama, and California.
Education & Training
- University of Pennsylvania Health SystemFellowship, Nephrology, 1993 - 1994
- University of Pennsylvania Health SystemFellowship, Nephrology, 1991 - 1992
- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1989 - 1990
- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1987 - 1989
- Georgetown University School of MedicineClass of 1987
Certifications & Licensure
- CA State Medical License 1990 - Present
- NJ State Medical License 1988 - 2025
- PA State Medical License 1990 - 2024
- MD State Medical License 1990 - 1992
- NY State Medical License 1990 - 1992
- OH State Medical License 1990 - 1992
- AL State Medical License 1991 - 1991
- Join now to see all
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- 12 citationsPharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.Michael A. Tortorici, Danielle Duffy, Rebecca Evans, John Feaster, Andreas Gille
Clinical Pharmacology in Drug Development. 2019-07-01 - 10 citationsModerate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.Andreas Gille, Danielle Duffy, Michael A. Tortorici, Samuel D. Wright, Lawrence I. Deckelbaum
Journal of Clinical Pharmacology. 2019-03-01 - 10 citationsEvaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.Paul A. Gurbel, Udaya S. Tantry, Denise D'Andrea, Thomas Chung, John H. Alexander
Journal of Thrombosis and Thrombolysis. 2018-05-01
Professional Memberships
- Fellow